Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for leniolisib

  1. Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)

    Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.

    Highly specialised technologies guidance
    Published
    23 April 2025

    Sections for HST33

  2. Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in children 4 to 11 years [TSID12190]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. First licensed treatment for ultra-rare immune disorder recommended

    Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.

    News
    Last updated
    13 March 2025